Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Current Assets (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Current Assets for 8 consecutive years, with $241.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 21.09% year-over-year to $241.4 million, compared with a TTM value of $241.4 million through Dec 2025, down 21.09%, and an annual FY2025 reading of $241.4 million, down 21.09% over the prior year.
  • Current Assets was $241.4 million for Q4 2025 at Arcturus Therapeutics Holdings, down from $249.2 million in the prior quarter.
  • Across five years, Current Assets topped out at $470.0 million in Q1 2021 and bottomed at $241.4 million in Q4 2025.
  • Average Current Assets over 5 years is $348.5 million, with a median of $361.4 million recorded in 2024.
  • The sharpest move saw Current Assets skyrocketed 637.14% in 2021, then crashed 41.4% in 2022.
  • Year by year, Current Assets stood at $379.0 million in 2021, then increased by 6.43% to $403.3 million in 2022, then fell by 4.15% to $386.6 million in 2023, then fell by 20.85% to $306.0 million in 2024, then decreased by 21.09% to $241.4 million in 2025.
  • Business Quant data shows Current Assets for ARCT at $241.4 million in Q4 2025, $249.2 million in Q3 2025, and $274.5 million in Q2 2025.